Image_3_Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis.TIF
Background: Peripheral T-cell lymphoma (PTCL) is an extensive class of biologically and clinically heterogeneous diseases with dismal outcomes. The histone deacetylase inhibitor (HDACi) romidepsin was approved for relapsed and refractory (R/R-PTCL) in 2011. This meta-analysis was performed to assess the efficacy and safety of romidepsin in PTCL.
Methods: We searched for articles on the HDAC inhibitor romidepsin in the treatment of PTCL in Embase, Web of Science, and PubMed. The methodology is further detailed in PROSPERO (CRD42020213651, CRD42020213553). The 2-year overall survival (OS), 2-year progression-free survival (PFS), and their corresponding to 95% confidence intervals (CIs) were measured. Besides, corresponding 95% CIs were pooled for the complete response (CR), partial response (PR), duration of response (DoR), and risk of adverse events (AEs).
Results: Eleven studies containing 388 patients were incorporated into the quantitative synthesis, of which R/R-PTCL patients were the dominant portion, accounting for 94.3% (366/388). For all studies, the CR rate was 20% (95% CI, 13–27%, random effects model), and the PR rate was 18% (95% CI, 12–25%, random effects model). The 2-year OS was 48% (95% CI, 38–59%, fixed effects model), and the 2-year PFS was 17% (95% CI, 13–21%, fixed effects model). There were no significant differences between romidepsin monotherapy and romidepsin plus additional drugs. Hematological toxicities, such as lymphopenia and granulocytopenia, remained the most continually happening grade 3 or higher AEs, accounting for 46 and 28%, respectively. None of the studies reported any drug-related mortality.
Conclusions: Considering that most of the included patients had R/R-PTCL, the addition of romidepsin significantly enhance the efficacy. And AEs were tolerable as the grade 3/4 AEs in romidepsin monotherapy was 7% (95% CI, 6–8%). It is imperative to further expand the first-line application of romidepsin and carry out personalized therapy based on epigenomics, which will improve the survival of PTCL patients.
Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020213651 and https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020213553.
History
References
- https://doi.org//10.1038/s41568-020-0247-0
- https://doi.org//10.1200/JCO.2015.63.5540
- https://doi.org//10.1200/JCO.2008.16.4558
- https://doi.org//10.1182/blood-2010-02-270785
- https://doi.org//10.1200/JCO.2012.44.7524
- https://doi.org//10.1056/NEJMra1805035
- https://doi.org//10.1182/hematology.2020000092
- https://doi.org//10.1038/s41571-019-0190-8
- https://doi.org//10.1182/hematology.2020000101
- https://doi.org//10.1093/nar/gkab052
- https://doi.org//10.1158/0008-5472.CAN-13-0890
- https://doi.org//10.1038/nrd4360
- https://doi.org//10.1038/leu.2016.357
- https://doi.org//10.1186/s13045-020-01006-w
- https://doi.org//10.1080/17460441.2017.1341487
- https://doi.org//10.1172/JCI69738
- https://doi.org//10.1182/blood-2010-10-312603
- https://doi.org//10.1136/bmj.g7647
- https://doi.org//10.1046/j.1445-2197.2003.02748.x
- https://doi.org//10.1182/blood.2020009004
- https://doi.org//10.1182/blood.2019001285
- https://doi.org//10.1182/blood-2017-09-806737
- https://doi.org//10.1080/10428194.2018.1515937
- https://doi.org//10.1186/s13045-016-0266-1
- https://doi.org//10.1200/JCO.18.00899
- https://doi.org//10.1200/JCO.2011.37.4223
- https://doi.org//10.1007/s12185-017-2286-1
- https://doi.org//10.1158/1078-0432.CCR-19-2152
- https://doi.org//10.1002/hon.2691
- https://doi.org//10.1186/1756-8722-7-11
- https://doi.org//10.1182/blood-2016-08-692566
- https://doi.org//10.1093/annonc/mdu443
- https://doi.org//10.2147/OTT.S189825
- https://doi.org//10.1634/theoncologist.2017-0524
- https://doi.org//10.1016/S2352-3026(20)30207-6
- https://doi.org//10.1200/JCO.2011.40.2719
- https://doi.org//10.1186/s40164-021-00203-8
- https://doi.org//10.1146/annurev-immunol-061020-053702
Usage metrics
Read the peer-reviewed publication
Categories
- Radiology and Organ Imaging
- Foetal Development and Medicine
- Obstetrics and Gynaecology
- Primary Health Care
- Medical and Health Sciences not elsewhere classified
- Dermatology
- Emergency Medicine
- Gastroenterology and Hepatology
- Geriatrics and Gerontology
- Intensive Care
- Medical Genetics (excl. Cancer Genetics)
- Nephrology and Urology
- Nuclear Medicine
- Orthopaedics
- Otorhinolaryngology
- Pathology (excl. Oral Pathology)
- Family Care